Zhang Xiaoyue, Lin Jie, Xu Hongpan, Zhou Yan, Mu Zhiyi, Shi Ruizhe, Lv Yalei
Oncology Department 4, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Department of Gastrointestinal Disease Center, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Front Immunol. 2025 May 6;16:1599100. doi: 10.3389/fimmu.2025.1599100. eCollection 2025.
Gastrointestinal (GI) cancers are main causes of poor health, with most remaining difficult to treat effectively. Identifying new targets for treatment is crucial for improving the efficacy of tumour therapies and enhancing patient quality of life. Anoctamin-1 (ANO1), a crucial component of calcium-activated chloride channels (CaCCs), is expressed widely in various cell types, including epithelial cells, vascular smooth muscle cells, and tumour cells, and influences cell proliferation and migration. Nonetheless, the exact pathways through which ANO1 contributes to malignant transformation and immune responses remain elusive. This review comprehensively examines the regulatory functions and potential therapeutic applications of ANO1 in GI cancers. The goal of this work is to offer new perspectives for further study on the role of ANO1 in gastrointestinal cancers and to support improvements in therapeutic strategies for cancer diagnosis and treatment through the targeting of ANO1.
胃肠道(GI)癌症是健康状况不佳的主要原因,大多数此类癌症仍然难以得到有效治疗。确定新的治疗靶点对于提高肿瘤治疗效果和改善患者生活质量至关重要。anoctamin-1(ANO1)是钙激活氯离子通道(CaCCs)的关键组成部分,在包括上皮细胞、血管平滑肌细胞和肿瘤细胞在内的各种细胞类型中广泛表达,并影响细胞增殖和迁移。尽管如此,ANO1促成恶性转化和免疫反应的确切途径仍不清楚。本综述全面研究了ANO1在胃肠道癌症中的调节功能和潜在治疗应用。这项工作的目的是为进一步研究ANO1在胃肠道癌症中的作用提供新的视角,并通过靶向ANO1支持改善癌症诊断和治疗的策略。